These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 34726183)

  • 1. Epidermal Hyperproliferation With Less Prominent Dermal Inflammation Is the Unique Histopathological Feature of the Refractory Lesions in Psoriasis Treated With Ustekinumab.
    Kim M; Yang S; Kim BR; Youn SW
    Am J Dermatopathol; 2022 Apr; 44(4):267-271. PubMed ID: 34726183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of ustekinumab 90 mg in patients weighing 100 kg or less: a retrospective, observational, multicenter study.
    Del Alcázar E; Ferran M; López-Ferrer A; Notario J; Vidal D; Riera J; Aparicio G; Gallardo F; Vilarrasa E; Alsina M; Puig L; Ferrándiz C; Carrascosa JM
    J Dermatolog Treat; 2020 May; 31(3):222-226. PubMed ID: 30883242
    [No Abstract]   [Full Text] [Related]  

  • 3. A randomized, double-blind, phase III study assessing clinical similarity of SB17 (proposed ustekinumab biosimilar) to reference ustekinumab in subjects with moderate-to-severe plaque psoriasis.
    Feldman SR; Narbutt J; Girolomoni G; Brzezicki J; Reznichenko N; Zegadło-Mylik MA; Pulka G; Dmowska-Stecewicz M; Kłujszo E; Rekalov D; Rajzer L; Lee J; Lee M; Rho YH
    J Am Acad Dermatol; 2024 Sep; 91(3):440-447. PubMed ID: 38685404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial.
    Blauvelt A; Lomaga M; Burge R; Zhu B; Shen W; Shrom D; Dossenbach M; Pinter A
    J Dermatolog Treat; 2020 Mar; 31(2):141-146. PubMed ID: 30799638
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis.
    Hayashi M; Umezawa Y; Fukuchi O; Ito T; Saeki H; Nakagawa H
    J Dermatol; 2014 Nov; 41(11):974-80. PubMed ID: 25346301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New onset or transition of disease state of psoriatic arthritis during treatment with ustekinumab: A single-center retrospective study.
    Asahina A; Umezawa Y; Momose M; Honda H; Yanaba K; Nakagawa H
    J Dermatol; 2017 Dec; 44(12):1380-1384. PubMed ID: 28771778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secukinumab and ustekinumab treatment in psoriatic arthritis: results of a direct comparison.
    Letarouilly JG; Flachaire B; Labadie C; Kyheng M; Cohen N; Sellam J; Richette P; Dieude P; Claudepierre P; Fautrel B; Houvenagel E; Nguyen CD; Guyot MH; Segaud N; Marguerie L; Deprez X; Salmon JH; Baudens G; Miceli-Richard C; Gervais E; Chary-Valckenaere I; Lafforgue P; Philippe P; Loeuille D; Richez C; Tubach F; Pham T; Flipo RM
    Rheumatology (Oxford); 2021 Jun; 60(6):2773-2782. PubMed ID: 33232465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An analysis of Drug Survival, Effectiveness, and Safety in Moderate to Severe Psoriasis Treated With Ustekinumab: An Observational Study of 69 Patients in Routine Clinical Practice.
    Salgüero Fernández I; Gil MH; Sanz MS; Gullón GR
    Actas Dermosifiliogr (Engl Ed); 2019 Apr; 110(3):244-246. PubMed ID: 29961546
    [No Abstract]   [Full Text] [Related]  

  • 9. Characterizing patients with psoriasis on injectable biologics adalimumab, etanercept, and ustekinumab: A chart review study.
    Zhang M; Goren A; Lee S; DiBonaventura MD; Olson WH
    J Dermatolog Treat; 2016 Aug; 27(4):339-45. PubMed ID: 26558924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database.
    Sruamsiri R; Iwasaki K; Tang W; Mahlich J
    BMC Dermatol; 2018 Jul; 18(1):5. PubMed ID: 29996929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retrospective, observational multicenter study of 141 patients treated with ustekinumab 90 mg.
    Llamas-Velasco M; Baniandrés O; Rivera R; Reymundo Jimenez A; Hospital M; García Zamora E; González-Cantero Á; Andrés Lencina JJ; Daudén E; de la Cueva P
    Dermatol Ther; 2020 Jul; 33(4):e13678. PubMed ID: 32447810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver Injury in Psoriasis Patients Receiving Ustekinumab: A Retrospective Study of 44 Patients Treated in the Clinical Practice Setting.
    Llamas-Velasco M; Concha-Garzón MJ; García-Diez A; Daudén E
    Actas Dermosifiliogr; 2015; 106(6):470-6. PubMed ID: 25912374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistent expression of interleukin-17 and downstream effector cytokines in recalcitrant psoriatic lesions after ustekinumab treatment.
    Kim BR; Kim M; Yang S; Choi CW; Lee KS; Youn SW
    J Dermatol; 2021 Jun; 48(6):876-882. PubMed ID: 33860544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
    Papp KA; Blauvelt A; Bukhalo M; Gooderham M; Krueger JG; Lacour JP; Menter A; Philipp S; Sofen H; Tyring S; Berner BR; Visvanathan S; Pamulapati C; Bennett N; Flack M; Scholl P; Padula SJ
    N Engl J Med; 2017 Apr; 376(16):1551-1560. PubMed ID: 28423301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of ustekinumab in a group of 22 elderly patients with psoriasis over a 2-year period.
    Megna M; Napolitano M; Balato N; Monfrecola G; Villani A; Ayala F; Balato A
    Clin Exp Dermatol; 2016 Jul; 41(5):564-6. PubMed ID: 27028505
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparative effectiveness of adalimumab versus ustekinumab in the treatment of severe chronic plaque psoriasis: The results based on data from the program "treatment of moderate and severe forms of plaque psoriasis (B.47)" of the National Health Fund in Poland.
    Owczarek W; Nowakowska A; Walecka I; Ciechanowicz P; Reich A; Lesiak A; Borkowska E; Śliwczyński A; Narbutt J
    Dermatol Ther; 2022 Jun; 35(6):e15481. PubMed ID: 35363386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation Between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis Treated with Ustekinumab.
    Hesselvig JH; Egeberg A; Loft ND; Zachariae C; Kofoed K; Skov L
    Acta Derm Venereol; 2018 Mar; 98(3):335-339. PubMed ID: 29110019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ustekinumab for the treatment of psoriasis: an evidence update.
    Yiu ZZ; Warren RB
    Semin Cutan Med Surg; 2018 Sep; 37(3):143-147. PubMed ID: 30215630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ustekinumab treatment in patients with psoriasis undergoing hemodialysis.
    Umezawa Y; Hayashi M; Kikuchi S; Fukuchi O; Yanaba K; Ito T; Asahina A; Saeki H; Nakagawa H
    J Dermatol; 2015 Jul; 42(7):731-4. PubMed ID: 25959602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse Medical Conditions Across Treatment Options in Patients With Psoriasis: A Claims-Based Analysis.
    Wu JJ; Armstrong A; Singh R; Cloutier M; Gauthier-Loiselle M; Gagnon-Sanschagrin P; Arikan D; Fleischer A; Guérin A; Ganguli A
    J Drugs Dermatol; 2018 Nov; 17(11):1211-1218. PubMed ID: 30500143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.